アルビモパンの市場：治療用途別、エンドユーザー別-2024-2030年の世界予測

アルビモパン市場規模は2023年に62億米ドルと推計され、2024年には65億1,000万米ドルに達し、CAGR 5.23%で2030年には88億7,000万米ドルに達すると予測されています。

アルビモパンは、末梢性作用ホルシ・オピオイド受容体拮抗薬に分類される医療用化合物です。アルビモパンは、特に腸に対するオピオイドの副作用を打ち消すように設計されているため、術後イレウス（腹部手術後に腸が一時的に麻痺し、正常な腸の機能が阻害される状態）の管理に役立ちます。外科手術、特に腹部手術の世界の増加は、アルビモパンのような術後ケアソリューションの需要増に直結しています。オピオイド誘発性合併症に対する認識と管理戦略の高まりは、アルビモパンのような効果的な薬剤の必要性をさらに高めています。ヘルスケア施設の改善や入院期間の短縮、医療費の削減がアルビモパンの臨床現場での採用を後押ししています。しかし、厳しい規制や長い承認プロセスが、アルビモパンの市場参入を遅らせる可能性があります。アルビモパンには副作用のリスクがあるため、ヘルスケアプロバイダーや患者の間で採用の課題が生じる可能性があります。さらに、新興経済諸国ではヘルスケア・インフラが発展し、外科手術が増加しているため、大きな成長機会となっています。医療施設や保険会社と協力して、アルビモパンを使用することの費用対効果を強調することで、市場の成長の可能性が生まれるかもしれません。

治療用途：オピオイド誘発性便秘を緩和する多様な応用範囲

アルビモパンはオピオイド誘発性便秘（OIC）に使用され、腸に対するオピオイド作用を阻害することにより、疼痛管理効果を損なうことなく便秘を緩和します。アルビモパンは、オピオイド治療を受けている患者において、第一選択薬の下剤が効かない場合に、便秘症状を管理するための重要な選択肢となります。アルビモパンは、POIの予防、つまり積極的なアプローチに適しており、胃腸の回復を早め、入院費用を削減することができます。アルビモパンは通常、選択的腸切除手術を受ける成人患者に使用されます。

エンドユーザー：術後イレウスの治療において、手術センターでアルビモパンへの嗜好が高まる

病院では、アルビモパンは、特に消化管を含む手術後の回復を促進するために主に使用されています。アルビモパンの必要性は、入院期間を短縮し、術後イレウス（POI）の発生率を低下させることにあります。外科センターでは、アルビモパンを腹部手術を受けた患者の回復を助けるために使用しています。POIを予防するアルビモパンの役割は、外科センターにとって重要な効率性と患者満足度の指標を維持する上で特に価値があります。

地域別インサイト

南北アメリカでは、米国とカナダがアルビモパン市場の最前線にあり、その主な理由はFDAの承認と多くの病院の術後ケアプロトコールへの採用です。高いヘルスケア支出、高度な医療施設の普及、継続的な研究が、この地域でのアルビモパンの利用に大きく貢献しています。欧州連合におけるアルビモパンの採用は国によって異なり、各国のヘルスケアシステムの方針、償還方法、術後ケアの革新に関する認知度によって異なります。アルビモパンの認知度と使用は、特に医療制度がしっかりしている湾岸協力会議（GCC）諸国において徐々に拡大しています。APAC地域では、中国におけるアルビモパンの需要が、外科手術の増加やヘルスケアセクターの拡大を背景に伸びています。最近の特許や調査により、アルビモパンへの関心が高まっており、特に日本では高齢者の術後回復を促進する効果が期待されています。インドにおけるアルビモパンの市場は、医療インフラが整備され、術後ケアに対する意識が高まっていることから、まだ始まったばかりです。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはアルビモパン市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、アルビモパン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.アルビモパン市場の市場規模および予測は？

2.アルビモパン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.アルビモパン市場の技術動向と規制枠組みは？

4.アルビモパン市場における主要ベンダーの市場シェアは？

5.アルビモパン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 腹部手術を含む外科的介入の増加
    • オピオイド誘発性合併症に対する認識と管理戦略の高まり
    • 世界中のヘルスケア施設の改善
  • 抑制要因
    • 厳しい規制と長い承認プロセス
  • 機会
    • アルビモパンの治療への応用を探求する研究開発イニシアチブ
    • 公的および民間のヘルスケアインフラへの投資の増加
  • 課題
    • アルビモパンに関連する副作用のリスク
• 市場セグメンテーション分析
  • 治療への応用：オピオイド誘発性便秘の緩和のための多様な応用範囲
  • エンドユーザー：術後腸閉塞の治療における外科センターでのアルビモパンの好感度が高まっている
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 アルビモパンの市場治療用途別

• オピオイド誘発性便秘
• 術後イレウス予防

第7章 アルビモパンの市場：エンドユーザー別

• 病院
• 外科センター

第8章 南北アメリカのアルビモパンの市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のアルビモパンの市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのアルビモパンの市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Hikma Pharmaceuticals、米国で胃腸の回復を促進するアルビモパンカプセルを発売
• 戦略分析と提言

第12章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ALVIMOPAN MARKET RESEARCH PROCESS
• FIGURE 2. ALVIMOPAN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ALVIMOPAN MARKET DYNAMICS
• FIGURE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 20. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ALVIMOPAN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ALVIMOPAN MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY OPIOID-INDUCED CONSTIPATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ALVIMOPAN MARKET SIZE, BY OPIOID-INDUCED CONSTIPATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ALVIMOPAN MARKET SIZE, BY POSTOPERATIVE ILEUS PREVENTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ALVIMOPAN MARKET SIZE, BY POSTOPERATIVE ILEUS PREVENTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ALVIMOPAN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ALVIMOPAN MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ALVIMOPAN MARKET SIZE, BY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ALVIMOPAN MARKET SIZE, BY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. AMERICAS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 20. AMERICAS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 21. AMERICAS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 22. AMERICAS ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 23. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 24. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 25. ARGENTINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 26. ARGENTINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 27. ARGENTINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 28. ARGENTINA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 29. BRAZIL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 30. BRAZIL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 31. BRAZIL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 32. BRAZIL ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 33. CANADA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 34. CANADA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 35. CANADA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 36. CANADA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 37. MEXICO ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 38. MEXICO ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 39. MEXICO ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 40. MEXICO ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 41. UNITED STATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 42. UNITED STATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 43. UNITED STATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 44. UNITED STATES ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 45. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 46. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 48. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 50. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 52. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 53. AUSTRALIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 54. AUSTRALIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 55. AUSTRALIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 56. AUSTRALIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 57. CHINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 58. CHINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 59. CHINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 60. CHINA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 61. INDIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 62. INDIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 63. INDIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 64. INDIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 65. INDONESIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 66. INDONESIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 67. INDONESIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 68. INDONESIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 69. JAPAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 70. JAPAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 71. JAPAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 72. JAPAN ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 73. MALAYSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 74. MALAYSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 75. MALAYSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 76. MALAYSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 77. PHILIPPINES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 78. PHILIPPINES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 79. PHILIPPINES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 80. PHILIPPINES ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 81. SINGAPORE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 82. SINGAPORE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 83. SINGAPORE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 84. SINGAPORE ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 86. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 88. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 89. TAIWAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 90. TAIWAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 91. TAIWAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 92. TAIWAN ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 93. THAILAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 94. THAILAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 95. THAILAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 96. THAILAND ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 97. VIETNAM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. VIETNAM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. VIETNAM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 100. VIETNAM ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 107. DENMARK ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 108. DENMARK ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 109. DENMARK ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 110. DENMARK ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 111. EGYPT ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 112. EGYPT ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 113. EGYPT ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 114. EGYPT ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 115. FINLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. FINLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. FINLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. FINLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. FRANCE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 120. FRANCE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 121. FRANCE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 122. FRANCE ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 123. GERMANY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. GERMANY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. GERMANY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 126. GERMANY ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 127. ISRAEL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 128. ISRAEL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 129. ISRAEL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 130. ISRAEL ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 131. ITALY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 132. ITALY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 133. ITALY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 134. ITALY ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 135. NETHERLANDS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 136. NETHERLANDS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 137. NETHERLANDS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 138. NETHERLANDS ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 139. NIGERIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. NIGERIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. NIGERIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 142. NIGERIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 143. NORWAY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 144. NORWAY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 145. NORWAY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 146. NORWAY ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 147. POLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 148. POLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 149. POLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 150. POLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 151. QATAR ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. QATAR ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. QATAR ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 154. QATAR ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 155. RUSSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 156. RUSSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 157. RUSSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 158. RUSSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 160. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 162. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 166. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 167. SPAIN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 168. SPAIN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 169. SPAIN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 170. SPAIN ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 171. SWEDEN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. SWEDEN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. SWEDEN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 174. SWEDEN ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 175. SWITZERLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 176. SWITZERLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 177. SWITZERLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 178. SWITZERLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 179. TURKEY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 180. TURKEY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 181. TURKEY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 182. TURKEY ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 188. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 190. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 191. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023

[189 Pages Report] The Alvimopan Market size was estimated at USD 6.20 billion in 2023 and expected to reach USD 6.51 billion in 2024, at a CAGR 5.23% to reach USD 8.87 billion by 2030.

Alvimopan is a medical compound categorized under the umbrella of peripherally acting μ-opioid receptor antagonists. Alvimopan is specifically designed to counteract the side effects of opioids on the bowel, thus aiding in the management of postoperative ileus, a condition where the bowel becomes temporarily paralyzed after abdominal surgery, inhibiting normal bowel functions. The global rise in surgical interventions, especially abdominal surgeries, directly correlates with the increasing demand for postoperative care solutions such as Alvimopan. Growing awareness and management strategies for opioid-induced complications further elevate the need for effective medications such as Alvimopan. Improved healthcare facilities and an emphasis on reducing hospital stays and healthcare costs propel the adoption of Alvimopan in clinical settings. However, strict regulations and long approval processes may delay market access for Alvimopan. Alvimopan carries the risk of side effects, which may create challenges for adoption among healthcare providers and patients. Moreover, developing healthcare infrastructure and increasing surgical procedures in emerging economies present significant growth opportunities. Collaborating with healthcare facilities and insurers to highlight the cost-effectiveness of using Alvimopan may create growth potential in the market.

Therapeutic Application: Diverse scope of applications for easing opioid-Induced constipation

Alvimopan is used in opioid-induced constipation (OIC) by blocking the opioid effects on the gut, thus easing constipation without compromising pain management efficacy. Alvimopan serves as a crucial option for managing constipation symptoms in opioid-treated patients, in failure of first-line laxatives. Alvimopan is preferred for preventing POI, a proactive approach, allowing for faster gastrointestinal recovery and reduced hospitalization costs. Alvimopan is typically reserved for adult patients, undergoing elective bowel resection surgery.

End-User: Increasing preference for alvimopan in surgical centers for treating postoperative ileus

In hospitals, Alvimopan is predominantly used to enhance postoperative recovery, particularly after surgeries involving the gastrointestinal tract. The need for Alvimopan in these settings is driven by its ability to reduce length of hospital stays and lower the rates of postoperative ileus (POI). Surgical centers use Alvimopan to aid in the recovery of patients undergoing abdominal surgeries. Alvimopan's role in preventing POI is particularly valuable in maintaining the efficiency and patient satisfaction metrics critical to the surgical centers.

Regional Insights

In the Americas region, the U.S. and Canada are at the forefront in the Alvimopan market, largely due to FDA approval and its inclusion in postoperative care protocols in numerous hospitals. High healthcare spending, widespread availability of advanced medical facilities, and ongoing research contribute to its substantial use in the region. Alvimopan's adoption in the European Union varies by country, depending on national healthcare systems' policies, reimbursement practices, and the extent of awareness about postoperative care innovations. The awareness and use of Alvimopan are gradually growing, particularly in Gulf Cooperation Council (GCC) countries with robust healthcare systems. In the APAC region, the demand for Alvimopan in China is growing, driven by increasing surgical procedures and an expanding healthcare sector. Recent patents and research have stirred interest in Alvimopan, especially for its potential benefits in enhancing postoperative recovery in the elderly population, which is significant in Japan. The market for Alvimopan in India is nascent, given the rising healthcare infrastructure and increasing awareness about postoperative care.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alvimopan Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alvimopan Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alvimopan Market, highlighting leading vendors and their innovative profiles. These include Adolor Corporation, Adooq Bioscience LLC, Hikma Pharmaceuticals PLC, Manus Aktteva Biopharma LLP, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Alvimopan Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Therapeutic Application
  • Opioid-Induced Constipation
  • Postoperative Ileus Prevention

• End-User
  • Hospitals
  • Surgical Centers

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Alvimopan Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alvimopan Market?

3. What are the technology trends and regulatory frameworks in the Alvimopan Market?

4. What is the market share of the leading vendors in the Alvimopan Market?

5. Which modes and strategic moves are suitable for entering the Alvimopan Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in surgical interventions including abdominal surgeries
    • 5.1.1.2. Growing awareness and management strategies for opioid-induced complications
    • 5.1.1.3. Improved healthcare facilities worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. Strict regulations and long approval processes
  • 5.1.3. Opportunities
    • 5.1.3.1. R&D initiatives for exploring therapeutic applications of alvimopan
    • 5.1.3.2. Increasing investments in public and private healthcare infrastructure
  • 5.1.4. Challenges
    • 5.1.4.1. Risk of associated side effects of alvimopan
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapeutic Application: Diverse scope of applications for easing opioid-Induced constipation
  • 5.2.2. End-User: Increasing preference for alvimopan in surgical centers for treating postoperative ileus
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Alvimopan Market, by Therapeutic Application

• 6.1. Introduction
• 6.2. Opioid-Induced Constipation
• 6.3. Postoperative Ileus Prevention

7. Alvimopan Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Surgical Centers

8. Americas Alvimopan Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Alvimopan Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Alvimopan Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Hikma Pharmaceuticals Launches Alvimopan Capsules for Enhanced Gastrointestinal Recovery in the US
• 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

• 12.1. Key Company Profiles
• 12.2. Key Product Portfolio